1 The effects of a single oral dose of enalapril 10 mg on serum ACE activity and blood pressure in relation to the ACE genotype were studied in 27 healthy men, n = 9 each of genotype DD, ID and II, in a parallel group study design. 2 Before treatment serum ACE activity differed significantly between the genotypes, with serum ACE activity 56% higher in DD than II subjects, and the genotype explaining 40% of between-subject variance in serum ACE activity. 3 After oral enalapril 10 mg the absolute fall in serum ACE activity was significantly larger in DD than II subjects at 2, 4, and 6 h (by 9.0 (95% CI 0.7-17.2), 10.7 (3.8-17.6), and 9.7 (2.8-16.6) nmol ml-l min-1 respectively), but not at 24 h (fall in II > DD by 1.1 (-8.9 to 6.7) nmol ml-' min-'). 
Introduction
Rigat et al. [1] have described an insertion/deletion (I/D) polymorphism of the angiotensin converting enzyme (ACE) gene consisting of the presence or absence of a 287 bp insert in intron 16 in chromosome 17q23 of the human genome. This polymorphism of the ACE gene is associated with differences in serum ACE activity, so that subjects with the genotype DD have markedly higher serum ACE activity than those of genotype II. The prevalence of the genotypes in European populations is approximately 28% for DD, 50% for ID and 22% for II [2] . The insertion/deletion genetic polymorphism polymorphism accounts for about 48% of the total phenotypic variance in serum ACE activity [1] . Circulating ACE is thought to reflect ACE release from tissue vascular sites, and the primary effect of the genotype may therefore be on levels of tissue ACE [3] . ACE concentrations in serum are not thought to be rate-limiting for the production of angiotensin II, but the role of tissue ACE in this respect is less clear [4] . It has been suggested that the renin-angiotensin system may have an higher serum ACE activity [5] . In animal models of hypertension polymorphisms in the ACE gene have been linked to regulation of blood pressure [5] . In human hypertension the relationship is less clear with opposing views on a possible association [6, 7] . ACE inhibitor drugs are used widely in the treatment of hypertension and heart failure. They reduce serum ACE activity, and some studies have shown a relation between reduction in serum ACE activity and falls of blood pressure [8] . 08 .30 h having refrained from smoking, caffeine or strenuous exercise for 12 h. Otherwise they had followed their normal diet prior to the study, and specifically sodium intake was not controlled or perturbed. They lay supine for 30 min before receiving a single 10 mg dose of enalapril orally. They were semi-recumbent for 6 h after taking enalapril and remained fasting except for a standard meal 4 h after enalapril. Blood pressure and heart rate were measured at 30, 15, 10, 5 and 0 min before enalapril and at 20 min intervals for 6 h post-dosing. Serum ACE activity was measured at 0 (pre-enalapril), 2, 4, 6 and 24 h.
Results
Comparability of groups (Table 1) Subjects from the three genotypes were of similar age but differed as regards weight, with ID subjects significantly heavier than those of DD or II genotype. Average baseline blood pressure was similar in the three groups. As anticipated [1] there was a significant relation between ACE genotype and serum ACE activity at baseline (P < 0.02 between groups), with DD subjects having mean serum ACE activity 56% higher than that of II subjects (Figure 1 ). The ACE genotype accounted for 40% of the between-subject variance in serum ACE activity at baseline.
Changes in serum ACE activity (Table 2, Figure 1) In all subjects serum ACE activity was reduced substantially 2 h after enalapril, and remained below baseline levels at 24 h. The serum ACE responses to enalapril differed significantly between the ACE genotypes, with the reduction significantly larger in ACE gene polymorphism and responses to enalapril Figure 1 ). The ACE genotype continued to explain approximately 40% of the between-subject variance in serum ACE activity at each time point after enalapril. The percent reduction in baseline ACE activity after enalapril showed a different pattern, with larger proportional falls in II than DD genotype subjects, but differences between the groups were small (Table 2) .
Changes in blood pressure
The average fall in mean arterial pressure in all subjects was 7 mm Hg (8%) in the 6 h after enalapril. There were no significant differences between the genotypes for blood pressure response, and in particular no consistent trend for the enalapril response to be larger or smaller in DD compared with II subjects (mean difference DD-II: 0.7 mm Hg). The 95% confidence interval makes unlikely differences in response between the genotypes larger than 4.1 mm Hg (DD > II) or 5.5 mm Hg (II > DD).
Changes in serum ACE activity vs blood pressure
In all 27 subjects the fall in mean arterial pressure averaged over 6 h after enalapril did not correlate with initial ACE activity, or with percent or absolute changes in serum ACE activity.
Discussion
This study confirms the relationship between ACE genotype and serum ACE activity [1] with the ACE genotype accounting for 40% of between-subject variance and DD subjects having serum ACE activity 56% higher than those of II genotype. As might be expected subjects with genotype DD, who had the highest serum ACE activity initially, had significantly larger falls in serum ACE activity at 2, 4 and 6 h after 10 mg enalapril when compared with the other genotypes. This difference was no longer evident after 24 h. In percentage terms subjects of genotype II, who had the lowest serum ACE activity initially, actually showed the largest fall in serum ACE activity, although the differences between the three genotypes were small. Enalapril did not abolish the difference between genotypes in serum ACE activity, with residual serum ACE remaining significantly higher in DD than II subjects at each time point. Despite enalapril treatment the ACE genotype continued to account for about 40% of the between-subject variance in serum ACE, and subjects of genotype DD had serum ACE values approximately twice those of genotype II. These observations relate to a relatively low single dose of enalapril, and it will be of interest to examine whether higher doses or chronic treatment abolish serum ACE differences between the genotypes. Johnston et al. [8] showed a close relation between reduction in serum ACE activity and the fall in blood pressure in hypertensive subjects after a single 10 mg dose of enalapril. In the present study blood pressure response did not correlate with percent or absolute reduction in ACE activity, or with initial serum ACE. There was no significant difference in hypotensive response between genotypes. Although subjects of DD genotype had higher serum ACE activity initially, and larger falls in serum ACE in response to enalapril, their blood pressure response was not different from those of the other genotypes. Shown by the 95% confidence intervals the study had sufficient power to exclude differences, in mean arterial pressure responses larger than 5.5 mm Hg (II > DD) or 4.1 mm Hg (DD > II).
In summary, the ACE genotype influences serum ACE activity under normal conditions and after a single oral dose of enalapril, and also predicts the acute responses of serum ACE activity to a single dose of enalapril. However we found no evidence that the ACE genotype predicts the acute pharmacodynamic response to enalapril. These observations relate to healthy subjects in normal sodium balance, who have only small blood pressure reductions with enalapril [12] , and do not preclude the possibility that the ACE genotype may predict the response of hypertensive patients to ACE inhibitor treatment.
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